The Technical Analyst
OpGen Inc [OPGN]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
OpGen Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-8.16% $0.563
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.11 mill |
| EPS: | -6.25 |
| P/E: | -0.0900 |
| Earnings Date: | Apr 24, 2024 |
| SharesOutstanding: | 12.62 mill |
| Avg Daily Volume: | 1.728 mill |
| RATING 2024-04-24 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0900 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0900 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.469 - 0.657 ( +/- 16.70%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Ben-tzvi Avraham | Buy | 100 000 | Common Stock |
| 2024-04-11 | Natan David | Buy | 100 000 | Common Stock |
| 2024-04-11 | Mcmurdo Matthew Charles | Buy | 100 000 | Common Stock |
| 2024-04-11 | Lazar David E. | Buy | 100 000 | Common Stock |
| 2024-04-05 | Lazar David E. | Buy | 200 000 | Series E Convertible Preferred Stock |
| INSIDER POWER |
|---|
| -75.97 |
| Last 97 transactions |
| Buy: 3 423 408 | Sell: 6 921 404 |
Forecast:
16:00 - $0.574
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.574
Forecast 2: 16:00 - $0.574
Forecast 3: 16:00 - $0.574
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.563 (-8.16% ) |
| Volume | 0.175 mill |
| Avg. Vol. | 1.728 mill |
| % of Avg. Vol | 10.15 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OPGN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OPGN
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
Last 10 Buy Signals
Latest Press Releases
2024-04-23 16:15:00 - Press Release
Opgen Receives Nasdaq Notice Regarding Delayed Form 10-k
Rockville, md., april 23, 2024 (globe newswire) -- opgen, inc. (nasdaq: opgn, “opgen” or “the company”) announced today that it received a notice from the nasdaq stock market llc (“nasdaq”) indicating that the company was not in compliance with nasdaq listing rule 5250(c)(1) due to the company not filing its annual report on form 10-k for the fiscal year ended december 31, 2023 (the “form 10-k”). nasdaq listing rule 5250(c)(1) requires listed companies to timely file all periodic reports with the securities and exchange commission (the “sec”). the company previously filed a form 12b-25 with the sec disclosing that it was unable to file the form 10-k by april 1, 2024 without unreasonable effort or expense.
2024-03-25 16:05:00 - Press Release
Opgen Announces Acquisition Of Preferred Stock By David Lazar
Rockville, md., march 25, 2024 (globe newswire) -- opgen, inc. (nasdaq: opgn, “opgen” or “the company”), announced today that the company entered into a securities purchase agreement with david e. lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of series e convertible preferred stock (“series e preferred stock”) of the company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million. the proceeds of the transaction will be used to repay and settle outstanding indebtedness and liabilities of the company and for other general corporate and operating purposes.
2023-11-14 16:30:00 - Press Release
Opgen Reports Third Quarter 2023 Financial Results And Provides Business Update
Rockville, md., nov. 14, 2023 (globe newswire) -- opgen, inc. (nasdaq: opgn, “opgen” or “the company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2023 financial and operating results.
2023-10-12 12:32:00 - Press Release
Opgen Enters Into Warrant Inducement Transaction For Up To $11.2 Million In Gross Proceeds
Rockville, md., oct. 12, 2023 (globe newswire) -- opgen, inc. (nasdaq: opgn) (“opgen” or “the company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the company for cash (the “existing warrants”), wherein the investor agreed to exercise the existing warrants to purchase up to a maximum of 10,892,728 common shares at an exercise price of $0.7785 per share. as part of the agreement, the existing holder has agreed to pay an additional $0.25 consideration per share, resulting in gross proceeds of up to approximately $11...
2023-08-10 16:15:00 - Press Release
Opgen Reports Second Quarter 2023 Financial Results And Provides Business Update
Rockville, md., aug. 10, 2023 (globe newswire) -- opgen, inc. (nasdaq: opgn, “opgen” or “the company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results. management will host an investor call to discuss quarterly results and provide a business update.
Latest News
2023-09-29 08:22:23 - InvestorPlace
Why Is OpGen (OPGN) Stock Up 115% Today?
OpGen (NASDAQ: OPGN ) stock is on the rise Friday after the precision medicine company withdrew a share offering. A filing with the Securities and Exchange Commission (SEC) has the company requesting the withdrawal of its Registration Statement on Form S-1.
2023-07-06 09:20:32 - Zacks Investment Research
Buy 5 Top-Ranked Stocks With Rising P/E in July
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OpGen (OPGN), Adaptimmune Therapeutics (ADAP), Valmont Industries (VMI), Versus Systems (VS) and Tradeweb Markets (TW).
2023-06-21 07:18:14 - Zacks Investment Research
Bet on DuPont Analysis to Pick 5 Stocks for Stellar Returns
Do you have more faith in DuPont analysis than simple ROE calculation? Tap PDD Holdings Inc. (PDD), OpGen (OPGN), AGCO (AGCO), A10 Networks (ATEN) and The Duckhorn Portfolio (NAPA).
2023-06-05 09:10:15 - Zacks Investment Research
Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), The RealReal (REAL), Trevena (TRVN), ChargePoint (CHPT) and Caterpillar (CAT).
2023-05-18 08:26:06 - Zacks Investment Research
Go Beyond Bargain Hunting, Buy 5 Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), Horizon Technology Finance (HRZN), Equity Commonwealth (EQC), NOV (NOV) and Spartacus Acquisition (NN).
2023-05-15 20:19:08 - Seeking Alpha
OpGen Inc. (OPGN) Q1 2023 Earnings Call Transcript
OpGen Inc. (NASDAQ:OPGN ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Oliver Schacht – President and Chief Executive Officer Albert Weber – Chief Financial Officer Conference Call Participants Pooya Hemami – Edison Group Yi Chen – H.C. Wainwright Operator Welcome to the OpGen First Quarter 2023 Earnings Call and Business Update.
2023-04-18 08:24:10 - Zacks Investment Research
Forget Bargain Hunting, Buy 5 Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Disney (DIS), Casey's General Stores (CASY), OpGen (OPGN), Accelerate Diagnostics (AXDX) and Nektar Therapeutics (NKTR).
2023-03-29 18:22:04 - Seeking Alpha
OpGen, Inc. (OPGN) Q4 2022 Earnings Call Transcript
OpGen, Inc. (NASDAQ:OPGN ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Oliver Schacht - President and CEO Albert Weber - CFO Conference Call Participants Nidhi Singh - Edison Group Yi Chen - H.C. Wainwright Operator Welcome to the OpGen Fourth Quarter and Full Year 2022 Earnings Call and Business Update.
2023-01-26 09:28:03 - PennyStocks
Penny Stocks To Buy Now? 7 To Watch With Big News this Week
Penny stocks with news that has turned heads in the stock market this week. The post Penny Stocks To Buy Now?
2022-12-14 06:00:00 - PennyStocks
The Impact of Market Trends on Penny Stocks Trading
How to use market trends to make money with penny stocks The post The Impact of Market Trends on Penny Stocks Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.